(19)
(11) EP 4 551 696 A2

(12)

(88) Date of publication A3:
29.02.2024

(43) Date of publication:
14.05.2025 Bulletin 2025/20

(21) Application number: 23836274.3

(22) Date of filing: 06.07.2023
(51) International Patent Classification (IPC): 
C12N 9/22(2006.01)
C12N 15/113(2010.01)
C12N 15/63(2006.01)
C12N 15/10(2006.01)
C07K 19/00(2006.01)
C12N 15/62(2006.01)
C12N 15/86(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 9/22; C12N 15/102; C12N 2310/20; C12N 15/902; C07K 2319/01; C07K 2319/09
(86) International application number:
PCT/US2023/069709
(87) International publication number:
WO 2024/011176 (11.01.2024 Gazette 2024/02)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 08.07.2022 US 202263359359 P

(71) Applicants:
  • The Regents of the University of California
    Oakland, CA 94607 (US)
  • Evercrisp Biosciences
    New York, NY 10169 (US)

(72) Inventors:
  • DOUDNA, Jennifer A.
    Berkeley, California 94705 (US)
  • KORTEMME, Tanja
    San Francisco, California 94143 (US)
  • JAGGER, Benjamin
    San Francisco, California 94143 (US)
  • KRIVACIC, Cody
    San Francisco, California 94143 (US)
  • CHEN, Kai
    Berkeley, California 94709 (US)
  • LIRAS, Spiros
    Cambridge, Massachusetts 02142 (US)
  • RUSU, Victor
    Cambridge, Massachusetts 02142 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) MODIFIED CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF